A Phase 2, Multi-Center, Open-Label Extension Study to Evaluate the Safety and Efficacy of 12 mg Proellex(Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis. [EXTENSION OF 700218273]

Trial Profile

A Phase 2, Multi-Center, Open-Label Extension Study to Evaluate the Safety and Efficacy of 12 mg Proellex(Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis. [EXTENSION OF 700218273]

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 06 Feb 2014 Actual start date has changed from 2013-10 to 2013-12 according to Clinical trial.gov record.
    • 06 Feb 2014 Status changed from not yet recruiting to withdrawn prior to recruitment according to Clinical trial.gov record.
    • 22 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top